A Solid-in-Oil Nanodispersion System for Transcutaneous Immunotherapy of Cow’s Milk Allergies

Kitaoka, Momoko; Xiao, Wei; Kong, Qingliang; Tahara, Yoshiro; Kamiya, Noriho; Goto, Masahiro

doi:10.3390/pharmaceutics12030205

Cited by 5 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The S/O nanodispersion enhanced the skin permeation of BLG into the dermis, and skewed the immune response toward Th1 immunity, indicating the amelioration of allergic symptoms. This effect was reinforced when resiquimod (R848) was included in IPM (42). Likewise, the T cell epitope peptide (7CrpR) was efficiently delivered via the S/O nanodispersion and decreased IgE levels in pollinosis model mice.…”

Section: Nano-drug Delivery Systemmentioning

confidence: 99%

Innovative delivery systems for epicutaneous immunotherapy

Wang,

Wu,

Wang

2023

Front. Immunol.

View full text Add to dashboard Cite

Allergen-specific immunotherapy (AIT) describes the establishment of peripheral tolerance through repeated allergen exposure, which qualifies as the only curative treatment for allergic diseases. Although conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have been approved to treat respiratory allergies clinically, the progress made is far from satisfactory. Epicutaneous immunotherapy (EPIT) exploits the skin’s immune properties to modulate immunological response, which is emerging as a promising alternative and has shown effectiveness in many preclinical and clinical studies for both respiratory and food allergies. It is worth noting that the stratum corneum (SC) barrier impedes the effective delivery of allergens, while disrupting the SC layer excessively often triggers unexpected Th2 immune responses. This work aims to comprehend the immunological mechanisms of EPIT, and summarize the innovative system for sufficient delivery of allergens as well as tolerogenic adjuvants. Finally, the safety, acceptability, and cost-effectiveness of these innovative delivery systems are discussed, which directs the development of future immunotherapies with all desirable characteristics.

show abstract

Section: Nano-drug Delivery Systemmentioning

confidence: 99%

Innovative delivery systems for epicutaneous immunotherapy

Wang,

Wu,

Wang

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Recently, Kitaoka et al 54 used a S/O nanodispersion system to deliver both the hydrophilic allergen molecules (β‐lactoglobulin) and the lyophilic adjuvant (R‐848) through the epidermis. The authors applied isopropyl myristate as an oil vehicle in the S/O nanodispersion and sucrose laurate L‐195 as a surfactant 55 .…”

Section: Noninvasive Transcutaneous Immunizationmentioning

confidence: 99%

“…50 This system is attractive as a nanocarrier for peptides such as antigens and vaccine components owing to the high encapsulation efficacy for hydrophilic molecules and capacity for coloading immunomodulatory agents like adjuvants. [51][52][53] Recently, Kitaoka et al 54 used a S/O nanodispersion system to deliver both the hydrophilic allergen molecules (β-lactoglobulin) and the lyophilic adjuvant (R-848) through the epidermis. The authors applied isopropyl myristate as an oil vehicle in the S/O nanodispersion and sucrose laurate L-195 as a surfactant.…”

Section: Solid-in-oil Systemsmentioning

confidence: 99%

Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives

Sallam

Prakash

Kumbhojkar

et al. 2021

Bioengineering & Transla Med

View full text Add to dashboard Cite

A growing variety of biological macromolecules are in development for use as active ingredients in topical therapies and vaccines. Dermal delivery of biomacromolecules offers several advantages compared to other delivery methods, including improved targetability, reduced systemic toxicity and decreased degradation of drugs. However, this route of delivery is hampered by the barrier function of the skin. Recently, a large body of research has been directed towards improving the delivery of macromolecules to the skin, ranging from nucleic acids to antigens, using noninvasive means. In this review, we discuss the latest formulation-based efforts to deliver antigens and nucleic acids for vaccination and treatment of skin diseases. We provide a perspective of their advantages, limitations and potential for clinical translation. The delivery platforms discussed in this review may provide formulation scientists and clinicians with a better vision of the alternatives for dermal delivery of biomacromolecules, which may facilitate the development of new patientfriendly prophylactic and therapeutic medicines.

show abstract

“…Clinical studies are necessary to confirm the efficiency of S/O nanodispersion-based TCIT against JCP. After these studies, S/O nanodispersions carrying specific antigens may be extended to treat other type 1 allergic diseases, such as other types of pollinosis, milk allergies [70], dust allergies, and cat allergies.…”

Section: Applications Of S/o Nanodispersions For Tcit Of Jcpmentioning

confidence: 99%

Solid-in-Oil Nanodispersions for Transcutaneous Immunotherapy of Japanese Cedar Pollinosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Japanese cedar pollinosis (JCP) is a common affliction caused by an allergic reaction to cedar pollen and is considered a disease of national importance in Japan. Antigen-specific immunotherapy (AIT) is the only available curative treatment for JCP. However, low compliance and persistence have been reported among patients subcutaneously or sublingually administered AIT comprising a conventional antigen derived from a pollen extract. To address these issues, many research studies have focused on developing a safer, simpler, and more effective AIT for JCP. Here, we review the novel antigens that have been developed for JCP AIT, discuss their different administration routes, and present the effects of anti-allergy treatment. Then, we describe a new form of AIT called transcutaneous immunotherapy (TCIT) and its solid-in-oil (S/O) nanodispersion formulation, which is a promising antigen delivery system. Finally, we discuss the applications of S/O nanodispersions for JCP TCIT. In this context, we predict that TCIT delivery by using a S/O nanodispersion loaded with novel antigens may offer an easier, safer, and more effective treatment option for JCP patients.

show abstract

A Solid-in-Oil Nanodispersion System for Transcutaneous Immunotherapy of Cow’s Milk Allergies

Cited by 5 publications

References 31 publications

Innovative delivery systems for epicutaneous immunotherapy

Innovative delivery systems for epicutaneous immunotherapy

Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives

Solid-in-Oil Nanodispersions for Transcutaneous Immunotherapy of Japanese Cedar Pollinosis

Contact Info

Product

Resources

About